What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.

Monica MehtaLawrence J PurpuraThomas H McConvilleMatthew J NeidellMichaela R AndersonElana J BernsteinDonald E DietzJustin LaracyShauna H GunaratneEmily Happy MillerJennifer ChengJason E ZuckerShivang S ShahShaoli ChaudhuriChristian A GordilloShreena R PatelTai Wei GuoLara E KaraaslanRan ReshefBenjamin A MikoJoan M BathonMarcus R PereiraAnne-Catrin UhlemannMichael T YinMagdalena E Sobieszczyk

Published in: PloS one (2021)

There was no evidence to support an improvement in hypoxemia or ventilator-free survival with use of tocilizumab 400 mg in the absence of corticosteroids. No increase in secondary bacterial infections was observed in the group receiving tocilizumab.

Keyphrases

rheumatoid arthritis
free survival
juvenile idiopathic arthritis
rheumatoid arthritis patients
disease activity
healthcare
acute respiratory distress syndrome
emergency department
mechanical ventilation
adverse drug